Immunological effects of a single hemodialysis treatment by Angeletti A. et al.
medicina
Review
Immunological Effects of a Single Hemodialysis
Treatment
Andrea Angeletti, Fulvia Zappulo, Chiara Donadei, Maria Cappuccilli , Giulia Di Certo,
Diletta Conte, Giorgia Comai, Gabriele Donati and Gaetano La Manna *
Department of Experimental Diagnostic and Specialty Medicine (DIMES), Nephrology, Dialysis and Renal
Transplant Unit, S. Orsola-Malpighi Hospital, University of Bologna, 40138 Bologna, Italy;
andrea.angeletti6@unibo.it (A.A.); fulvia.zappulo@studio.unibo.it (F.Z.); chiara.donadei@studio.unibo.it (C.D.);
maria.cappuccilli@unibo.it (M.C.); giulia.dicerto@studio.unibo.it (G.D.C.); diletta.conte2@unibo.it (D.C.);
giorgia.comai@aosp.bo.it (G.C.); gabriele.donati@aosp.bo.it (G.D.)
* Correspondence: gaetano.lamanna@unibo.it; Tel.: +39-051-2144577
Received: 21 January 2020; Accepted: 10 February 2020; Published: 12 February 2020


Abstract: Immune disorders, involving both innate and adaptive response, are common in patients
with end-stage renal disease under chronic hemodialysis. Endogenous and exogenous factors, such
as uremic toxins and the extracorporeal treatment itself, alter the immune balance, leading to chronic
inflammation and higher risk of cardiovascular events. Several studies have previously described
the immune effects of chronic hemodialysis and the possibility to modulate inflammation through
more biocompatible dialyzers and innovative techniques. On the other hand, very limited data are
available on the possible immunological effects of a single hemodialysis treatment. In spite of the
lacking information about the immunological reactivity related to a single session, there is evidence
to indicate that mediators of innate and adaptive response, above all complement cascade and T
cells, are implicated in immune system modulation during hemodialysis treatment. Expanding our
understanding of these modulations represents a necessary basis to develop pro-tolerogenic strategies
in specific conditions, like hemodialysis in septic patients or the last session prior to kidney transplant
in candidates for receiving a graft.
Keywords: complement; hemodialysis; immune response; inflammation; kidney transplant;
lymphocytes; single dialysis session
1. Introduction
Patients with end stage renal disease (ESRD) are known to have an increased risk of cardiovascular
morbidity and mortality, related to traditional (diabetes mellitus, hypertension, dyslipidemia, and old
age) and non-traditional risk factors, including systemic inflammation and immune deficiency [1–4].
Patients affected by ESRD receiving chronic hemodialysis usually present immune disorders, not
solely related to the primary renal disease, which involve both innate and adaptive immune systems [5].
The consequent imbalance between pro- and anti-inflammatory mechanisms enhances the risk for
cardiovascular disease, infections, and malignancy [6,7], accounting for the elevated morbidity and
mortality rates in uremic patients [8,9].
Kidney function loss is progressively accompanied by a reduction of naïve T cells, resulting in
an inadequate immune response to antigens [10]. Previous studies have proven that patients under
chronic hemodialysis treatment have immune dysfunction compared to healthy subjects, mainly
due to the pro-inflammatory phenotypes of monocytes [11], the inverted CD4+/CD8+ ratio, the
accumulation of differentiated T cells, and a significant reduction of naïve T cells [12–14]. These
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immune disturbances are responsible for several effects, namely increased susceptibility to developing
bloodstream infections [15] or deficiencies in the immune response to vaccinations [16].
However, while there are plenty of data on the immunological effects of chronic hemodialysis, how
the single hemodialysis treatment acts on the immune system is still far to be completely elucidated.
A transient immune effect of hemodialysis may have a potential impact in different settings, such as
delayed graft function in the early stages of kidney transplant or acute kidney injury during sepsis. This
narrative review summarizes the current knowledge on the immunogenicity of the single hemodialysis
treatment, with a particular focus on innate and adaptive immunity.
2. Innate Immune Response During a Single Hemodialysis Treatment
2.1. Complement System
The complement system is part of the innate immune response with the main function of protecting
the host from foreign pathogens [17–19]. The complement cascade is activated by the lectin pathway,
the classical pathway and the alternative pathway, all of them converging on an enzymatic multimeric
protein complex, the C3 convertase [18]. C3 cleavage produces C3a and C3b, the latter eliciting the
formation of C5 convertase. C5 cleavage leads then to the assembly of the membrane attack complex
(MAC, C5b-9). Besides MAC, soluble and surface-bound split products, including C3a, C3b, iC3b,
C3dg, and C5a, are implicated in inflammatory response [20].
In 1977, Craddock et al. firstly described the possible pathological mechanisms for acute pulmonary
dysfunction, a cardiopulmonary complication occurring in the first phase of the dialysis session with
cellophane-membrane, as a consequence of a complement-mediated leukostasis (Table 1) [21]. The
authors observed a severe transient neutropenia and a reduction of monocytes in the first hour of
treatment, with activation of C3 and factor B, another serum protein of the alternative pathway [18].
During hemodialysis sessions, the dialysis membrane or the catheters may be coated with complement
components, followed by neutrophil adhesion [22]. Several studies agree that in the course of
hemodialysis sessions, the C3/C3d ratio and soluble C5b-9 in plasma increase up to 70% [23–25];
however, which complement pathway is mainly involved in the activation of complement cascade is
still to be defined.
The alternative pathway is known to affect immunity during hemodialysis. In healthy conditions,
the alternative pathway is continuously activated by the hydrolysis of C3 on cell surfaces and this
activation is balanced by circulating and cell surface regulatory factors [20]. During hemodialysis
treatment, a transient loss of complement inhibitors via absorption from dialysis membrane can generate
a temporary break of the stability between positive and negative regulators of the complement cascade.
A proteomic analysis by Mares et al. showed that hemodialysis polysulfone membranes adsorb
complement inhibitor factor H and clusterin (Table 1) [26]. Factor H is an inhibitor of C3 convertase,
while clusterin prevents terminal cascade activation blocking the formation of C5b-9. The recruitment
of these inhibitors by the dialysis membrane might therefore trigger complement activation. The
absorption of properdin to the dialyzer, the only known positive regulator of complement activation that
stabilizes the C3bBb complex leading to increased activity of the alternative pathway [18], corroborates
the hypothesis on the contribution of alternative pathway activation during hemodialysis [27].
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Table 1. Major published observational clinical studies reporting the effects of single hemodialysis treatment on the immune system.
Reference Study Design Patients Endpoints Results
Innate Immunity
Craddock PR, 1977 Observational prospective 34 hemodialysis patients with leukopeniaduring hemodialysis sessions
Detection of mechanisms for acute pulmonary
dysfunction reported in the first hour of
hemodialysis with cellophane membranes
15/34 had impaired pulmonary function
with transient neutropenia and reduction
of monocytes during the first hour of
hemodialysis sessions with activation of C3
and factor B
Mares J, 2010 Observational prospective 16 hemodialysis patients with polysulfonedialyzers
Leukocyte counts and complement components
levels were monitored during hemodialysis in
serum and equates
C3c, ficolin-2, mannan-binding lectin serine
proteases, and properdin were enriched in
equates and decreased in serum.
Poppelaars F, 2018 Observational prospective 55 hemodialysis patients To correlate cardiovascular event with plasmalevels of MBL, properdin, and C3d/C3 ratio
Lower levels of MBL and properdin in
patient cardiovascular events
Adaptive Immunity
Borges A, 2011 Cross-sectional 47 hemodialysis patients (12 evaluated beforeand after hemodialysis sessions)
Characterization of T lymphocyte phenotype
and apoptosis
The hemodialysis procedure contributed to
the development of T-cell lymphopenia, at
least in part, by apoptosis induction of
CD8+ T cells
Martinez-Miguel P, 2014 Observational prospective 30 hemodialysis patients with high-fluxpolymers To evaluate monocyte activation
No change after a single hemodialysis
treatment
Almeida A, 2015 Observational prospective 17 hemodialysis and diabetic patients
To assess the expression of T cell activation
markers and quantify inflammatory cytokines
before and after a single hemodialysis session
CD25+ cells and CD8+ CD25+ increased
significantly, while CD69 T cells and CD4+
CD25+ significantly decreased after the
hemodialysis session
Lisowska KA, 2019 Observational prospective 14 hemodialysis patients To investigate the effect of the singlehemodialysis session on T lymphocyte subsets
Increased CD4+/CD8+ ratio as a
consequence of the reduction of CD8+ T
Mai K, 2019 Observational prospective 15 ESRD patients receiving hemodialysistreatment before renal transplant
Alterations of adaptive immune response to
polynephron membrane
During the first hour there was an increase
in CD4+ T cells and activated CD4+
HLA-DR+ T cells, with a decrease of CD8+
T cells and CD8+ HLA-DR+ T cells
ESRD, end stage renal disease; MBL, mannose binding leptin.
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Likewise, the lectin pathway is involved in complement activation during hemodialysis procedure.
Filcolin-2, one of the few molecules known to be a trigger of the lectin pathway [28], was measured
through mass spectrometry assay in the plasma and in the eluates of 16 patients during hemodialysis
with polysulfone membranes: the ficolin-2 eluate/plasma ratio significantly increased during the
treatment, suggesting a possible specific adsorption by the membrane [26]. Similar findings were
reported in a different tandem mass spectrometry on eluates and serum samples of five patients during
the hemodialysis session: the eluate intensity of ficolin-2, clusterin, complement C3c fragment, and
apolipoprotein A1 differed significantly from the counterpart serum levels, implying preferential
adsorption to the polysulfone dialyzers [27]. The reduction of such factors in bloodstream was
associated with a serum increase of C5a and leukopenia during hemodialysis, and a higher incidence
of cardiovascular events was found in patients with lower serum levels of mannose binding leptin
(MBL) [29,30]. Notably, this relationship was not correlated with other traditional cardiovascular risk
factors (Table 1) [30].
Lastly, the classical pathway may also contribute to the complement activation through the
adhesion of C1q on membrane-adsorbed immunoglobulin G (IgG), although conflicting results are
available in the literature [31].
The activation of complement cascade may be further sustained by the covalent binding of C3b on
nucleophilic surface, characterized by the combination of oxidized lipids of blood vessels and dialysis
synthetic or cellulosic polymeric membranes coated with albumin, IgG, lipopolysaccharide, and other
non-pathological bacteria commonly present in water or dialysis solutions [32].
In conclusion, despite the remarkable developments in the biocompatibility of hemodialysis,
complement activation remains a significant concern in the single hemodialysis treatment, mainly
through alternative pathway and lectin pathway. Short-term effects of the complement system are the
enhancement of inflammation and coagulation, while long-term complications include fibrosis and
cardiovascular events.
2.2. Cellular Components
Besides the lack of a full comprehension of the immune reactivity against biomaterials, emerging
evidence indicates that innate immune cells, mostly neutrophils and macrophages, are essential players
in the initial phases of the immune response [33].
While blood flows through the dialysis membranes, synthetic materials elicit a foreign body reaction
characterized by recruitment of neutrophils and monocytes [34,35], which release pro-inflammatory
cytokines, namely interleukin 1 (IL-1), interleukin 6 (IL-6), and tumor necrosis factor-α (TNF-α) [36,37].
Therefore, the measurement of activated monocytes provides useful information on dialyzer
biocompatibility [38].
Previous in vitro studies explored the effect of inflammatory molecules released by activated
monocytes on endothelial cells (ECs), co-culturing CD14+ CD16+ monocytes with human umbilical
vein endothelial cells (HuVECs). Increased apoptosis and radical-oxygen-species (ROS) activity was
reported in HuVECs co-cultured with monocytes [39], confirming the hypothesis that oxidative stress
triggered by microinflammation in the ECs results in endothelial injury [40]. Successive evidence in
humans revealed how CD14+CD16+ monocytes derived from chronic kidney disease patients have
an increased adhesion ability to ECs [41]. Moreover, hemodialysis patients display higher relative
counts of CD14+CD16+ monocytes compared to peritoneal dialysis patients, and a relationship was
found between increased CD14+CD16+ monocytes and endothelial damage [42]. Clinical studies
investigating different types of hemodialysis membranes report indeed discordant results on the
efficacy of the different dialyzers in reducing markers of inflammatory and procoagulant state, namely
molecules involved in leukocyte, platelet and endothelial activation [43,44]. A single hemodialysis
session with low-flux membranes (cellulose-based and polysulfone membranes) did not seem to affect
blood levels of TNF-α, interleukin-6, P-selectin, and coagulation factors [43]. In an observational
prospective study on 30 patients undergoing hemodialysis with high-flux polymers, polysulfone
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or polyethersulfone, Martinez-Miguel et al. evaluated whether the use of more biocompatible
membranes could reduce monocyte activation and the in vitro ability of circulating cells to damage
endothelial monolayers. When compared to two weeks of hemodialysis with low-flux polysulfone,
the use of polyethersulfone membrane resulted in decreased adhesion of monocytes to ECs, reduced
monocyte-induced cellular toxicity and lower expression of endothelin-converting enzyme-1 (ECE-1),
a protein involved in endothelin synthesis. However, these effects were not reported after a single
hemodialysis treatment, suggesting a cumulative effect that might be explained by the continuous use
of such high-quality dialyzers (Table 1) [45].
Besides dialysis membranes, the synthetic vascular access also contributes to the modulation of
inflammatory response during the hemodialysis session. In a prospective observational study enrolling
100 chronic hemodialysis patients, we previously demonstrated that such condition is characterized by
an increased inflammatory state: compared to healthy subjects, the hemodialysis patients revealed
lower serum albumin levels, increased C-reactive protein (CRP), lower absolute monocyte count,
but increased expression on monocyte surface of cell activation marker CD14. When comparing the
patients grouped according to the type of vascular access, we found that the ones with arteriovenous
graft and tunneled-cuffed-catheter displayed higher circulating levels of inflammation markers (CRP,
IL-6, and TNF-α), increased expression on monocyte surface of cell activation markers (CD14, CD44,
and CD32), and higher relative number of monocytes with a senescent phenotype (CD14+ CD32+)
than those with a native fistula [46]. These results probably reflect the prolonged and continued use of
central venous catheter or graft, which determines either the contact of the monocytes with an artificial
material or monocyte activation after subclinical infection [47,48].
Taken together, all these data suggest that the type of vascular access may play a differential role
in promoting an inflammatory response. However, despite the presence of some limited experiences,
exhaustive reports describing the defined effects of a single hemodialysis session on white blood cells
are still lacking.
Finally, also the quality of dialysis water represents one of the modifiable uremia-induced risk
that could cause inflammation [49]. The current systems for water treatment are not able to remove
endotoxins, bacteria and their products or short bacterial DNA fragments, that given their small size,
easily pass thought the dialyzer membrane into the bloodstream [50].
We have previously reported that hemodialysis patients treated with ultrapure dialysate had
lower rate of lesions from β2-microglobulin-related amyloidosis and reduced CRP compared to those
who had undergone dialysis with no ultrapure dialysate. These findings can be explained by the better
bacteriological quality of the water [51].
In order to investigate the possible pro-inflammatory effect of dialysis water, Di Iorio et al.
investigated the ability of an ultrafilter to improve the quality of dialysis water and the effect on
cytokine profiles in 33 stable hemodialysis patients. The authors observed decreased levels of
pro-inflammatory cytokines and increased levels of anti-inflammatory cytokines in patients treated
with ultrapure dialysate [52].
Moreover, Kwan et al. demonstrated that ultrapure dialysate resulted in lower levels of circulating
endotoxins with no differences in bacterial DNA levels, which resulted in less severe vascular stiffness
and improvement of systemic inflammation [53].
These results support the hypothesis that circulating bacteria contribute to maintaining a systemic
inflammatory status.
3. Adaptive Immune Response during Hemodialysis Treatment
3.1. T Cells
Several studies have shown the alteration of T cell function in ESRD [54], but the mechanisms
are still to be clarified, and may be only partially explained as the consequence of higher levels of
proinflammatory cytokines in uremic serum. It is known that conventional T cells are reduced in ESRD
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patients due to the increased apoptosis rate and reduced proliferation [55]. However, pathogenetic
hypotheses on T cells dysfunction are not definitive and need more experimental data.
Mansouri et al. described a marked reduction of Th2 and regulatory T cells (Tregs) in patients
receiving chronic hemodialysis compared to healthy subjects [56].
More recently, Lisowska et al. investigated the effect of a single hemodialysis session on T
lymphocyte subsets, and observed an increased CD4+/CD8+ ratio as a consequence of the reduction
of CD8+ T cells and not of the increase of CD4+ T cells (Table 1) [57]. These findings are consistent
with a previous study indicating that hemodialysis procedures are, at least in part, responsible for the
development of T cell lymphopenia due to the induction of apoptosis (Table 1) [58]. Data from our
group and other authors highlighted the immunological effect of erythropoietin (EPO) in counteracting
T cell effects: EPO ligation of its receptor on CD4+ T cells has been proven to directly prevent Th17
generation and to induce trans-differentiation of Th17 into IL-17-Foxp3+ CD4+ T cells, downregulating
the pro-inflammatory T cell response [59–65]. Recombinant human erythropoietin (rhEPO) is usually
administered at the end of hemodialysis treatment, therefore it represents a further variant to consider
in the modulation of the immune system of the single hemodialysis.
The reiteration of the above described phenomena during the many hemodialysis sessions that
ESRD patients chronically receive may lead to the exhaustion of the lymphocyte activation capacity, a
phenomenon known as stress-induced premature senescence [14]. Litjens et al. postulated that the
drop in the number of naïve T cells in hemodialysis is explained by the impaired thymic output of naïve
T cells with deficient proliferation and disrupted homeostasis in the periphery [66]. Moreover, the same
group demonstrated that the decline of renal function is correlated with the activation of premature
T cell ageing of both CD4+ and CD8+ T cells [67]. Hemodialysis is also associated with a moderate
increase of memory T cell senescence in patients over 50 years of age [14]. A recent investigation
by Almeida et al. in a cohort of 17 patients with diabetic kidney disease undergoing hemodialysis
reported that a single hemodialysis treatment triggered activation of total T cells, in particular CD8+
CD25+ lymphocytes, a subset of activated effector T cells (Table 1) [68]. Unfortunately, the lack of
characterization with regulatory T cell markers, such as Foxp3, does not allow us to draw further
conclusions from this finding.
Hence, hemodialysis sessions represent a really important factor contributing to the immune
deficiency usually described in patients with ESRD but, on the other hand, they also seem to stimulate T
cell activation, perhaps secondary to the effects of innate immune factors, like complement components
and monocytes.
3.2. B Cells
B lymphocytes are in charge of the adaptive immune response by secreting antibodies following
contact with antigens. In the T cell-dependent response, antigens activating cells need the help of T cells,
which can be impaired by hemodialysis treatment. Therefore, hemodialysis is generally associated
with a diffuse reduction of B cell subpopulations [69].
In a case–control prospective observational study, Pahl et al. proved how patients receiving chronic
hemodialysis treatment are characterized by lymphopenia, including a reduced count of B lymphocytes,
when compared to healthy subjects, despite similar serum levels of B-cell activating factor (BAFF) and
interleukin-17 (IL-17) between the two groups. The authors also reported a reduced expression of
BAFF and IL-17 receptors on the surface of CD19+ CD10+ B-cells. Moreover, no differences in terms of
apoptosis of B cells between hemodialysis patients and control subjects were found [70]. In contrast,
in a case–control study including 36 hemodialysis patients and 32 pre-dialysis uremic subjects, an
increased apoptosis rate of B cells was observed in hemodialysis group, probably due to the reduced
expression of Bcl-2, a regulator protein that modulates cell death [71]. In a nutshell, the reduction of B
cells may be a consequence of both the increased apoptosis and downregulation of BAFF receptors.
In hemodialysis patients, despite their reduced number, B cells have a significant ability to release
pro-inflammatory cytokines, like TNF-α and IL-6 [36]. A more recent study, analyzing the immune
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phenotype of B cells in 27 hemodialysis patients vs healthy subjects, reported a significant decline of
immature B cells and an increase of memory B cells [72]. Nevertheless, the current knowledge of the
effects of a single hemodialysis session on B cells is still limited.
4. Possible Role of Hemodialysis in Early Stages of Kidney Transplant: Pro- or Anti-Tolerogenic
Effects?
Kidney transplant represents the best treatment option for ESRD. However, due to the scarcity of
deceased and living donors, the majority of ESRD patients need to receive renal replacement therapy
for a median time of 5 years, according to the United Network for Organ Sharing (UNOS) in the United
States. It is well established that the time spent on the waiting list impacts negatively on long-term
outcomes of transplant [73]. On the other hand, the impact of dialysis modality is still debated. It has
been recently reported that pre-transplant patients on peritoneal dialysis show a significantly lower
risk of delayed graft function after transplant than hemodialysis patients [74,75].
In a recent observational study on 15 patients eligible for renal transplantation receiving
hemodialysis, Mai et al. investigated leukocytes subsets, complement activation, and concentrations
of several pro-inflammatory cytokines before, during and after a hemodialysis session. In the first
hour, they described a rise in CD4+ T cells and activated CD4+ HLA-DR+ T cells, with a decrease of
CD8+ and CD8+ HLA-DR+ subsets. The counts of CD3+ lymphocytes expressing the early activation
marker CD25 were also increased over the whole observation period. Moreover, the authors reported
a reduction in naïve T cells during hemodialysis, feasibly due to the activation and subsequent
differentiation to effector or memory cells after contact with the dialysis membrane. Furthermore,
they observed a rise in CD8+ CCR5+ T cells that are crucial for the migration of lymphocytes. Tregs
and HLA-DR+ Tregs increased significantly in the course of hemodialysis. In summary, the authors
showed an increase in cells generally responsible for graft rejection and a slight rise in cells that induce
tolerance. Based on previous results, Mai and colleagues suggest avoiding short-time dialysis before
kidney transplantation (Table 1) [76]. Different studies have reported contrasting results on the effect of
pre-transplant hemodialysis modality on kidney transplant outcomes [77], but further investigations
are necessary to draw a definitive conclusion.
5. Single Hemodialysis Treatment and Immune System: Current Knowledge and Future Insights
Nowadays, the approach to dialysis in common clinical practice often follows a “one-size-fits-all”
rule rather than a prescription of the best hemodialysis treatment tailored to different types of patients
(Table 2). A better comprehension of the changes occurring in innate and adaptive immune responses
during a single hemodialysis treatment (Figure 1) is essential for providing a personalized therapy,
based on renal disease and comorbidities [78,79], also considering the synergistic contribution of
uremia and the hemodialysis procedure itself to impaired immune function in ESRD.
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Table 2. Current criteria used in our Center for the prescription of hemodialysis treatment.
Normal Diabetes Albumin < 4 gr% Diabetes Albumin < 4 gr% CardiacDisease Hypotension Allergies
HD Technique HD low/high flux HD high flux On-line HDF (convection target > 20L/session)
High Flux HD
On-line HDF (convection target
> 20 L/session)
Dialyzer Synthetic Synthetic Synthetic Bisfenol-freePVP-free
Dialysate flow 500 mL/min 500 mL/min 500 mL/min 500 mL/min
Dialysate composition
Na+ 140 mEq/L
K+ 2.5–3 mEq/L
Ca++ 1.5 mmol/L
Na+ 140 mEq/L
K+ 2.5–3 mEq/L
Ca++ 1.5 mmol/L
Na+ 140 mEq/L
K+ 2.5–3 mEq/L
Ca++ 1.5 mmol/L
Na+ 140 mEq/L
K+ 2.5–3 mEq/L
Ca++ 1.5 mmol/L
Ultrafiltration rate max 10 mL/kg/hour max 10 mL/kg/hour max 10 mL/kg/hour max 10 mL/kg/hour
Anticoagulation LMWH LMWH LMWH LMWH
Length (according to clinical status) 210-270 min 210-270 min 210-270 min 210-270 min
Rhythm (according to clinical status) 1->2->3->4 times/week 1->2->3->4 times/week 1->2->3->4 times/week 1->2->3->4 times/week
HD, hemodialysis; HDF, hemodiafiltration; LMWH, low-molecular-weight heparin; PVP, polyvinylpyrrolidone.
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Figure 1. Effects of hemodialysis on innate and acquired immunity. BAFF, B-cell activating factor; EC, endothelial cells; EPO, erythropoietin; IL-1, interleukin 1; IL-6, 
interleukin 6; ROS, radical-oxygen-species; TNF-α, tumor necrosis factor alpha. 
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Figure 1. Effects of hemodialysis on innate and acquired immunity. BAFF, B-cell activating factor; EC, endothelial cells; EPO, erythropoietin; IL-1, interleukin 1; IL-6,
interleukin 6; ROS, radical-oxygen-species; TNF-α, tumor necrosis factor alpha.
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While recent research and technology has led to great improvements in the field of dialysis
membranes, less information is available on the immunological reactivity related to the single dialysis
session, mostly derived from old studies with poorly representative populations, where patients were
treated with less biocompatible dialyzers compared to the synthetic alternatives currently in use [80].
Increasing our awareness on this issue will open a new scenario for the development of pro-tolerogenic
strategies in particular clinical settings, like hemodialysis in septic patients or the last dialysis session
prior to kidney transplantation in candidates for receiving a graft.
6. Conclusions
To summarize, although the effect of the single session on immune response is still far to be fully
elucidated, emerging evidence indicates the existence of an interplay between mediators of innate and
adaptive response, above all complement cascade and T cells.
For these reasons, it is essential to focus future research on the characterization of the acute
responses of the innate and the adaptive immune system in light of the novel biocompatible
hemodialysis membranes.
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